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Abstract 
The effects of chronic maternal perinatal nimodipine treatment on the immunocytochemical distribution of theCa 2 +-binding 
proteins parvalbumin (PV) and S-100/3 in neocortex and hippocampus were studied at the age of postnatal day (PD) 5, 7, t0, 14 
and 20. The Ca 2÷ antagonist nimodipine (1000 ppm BAY e 9736 in daily food) was administered to pregnant rats starting at 
postconceptual day 11. The expression of PV exemplified in layer V of parietal and retrosplenial cortex and in all hippocampal 
layers of CA1 and CA3 was enhanced by more than two-fold in the offspring of nimodipine-treated dams at PD 10 compared 
with placebo-treated animals. The difference was no longer present at PD 14 and 20. Nimodipine administration also 
significantly increased the number of S-100/3-immunoposltive glial cells in upper neocortical layers I-III at PD 5 and 7. Again, 
the difference between imodipine and placebo-treated animals disappeared after PD 10. The data indicate an accelerated 
development of PV and S-100 immunoreactivity in the postnatal forebrain as a result of perinatal blockade of the L-type Ca 2÷ 
current. 
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I. Introduction 
Ca 2+ ions play a pivotal role in a large number of 
processes in the brain. The intracellular free Ca 2+ 
concentration [Ca2+] i has been proposed to control 
events, such as transmitter release, membrane perme- 
ability and activation of several enzymes and genes 
[10,21]. Processes accompanying cellular plasticity are 
also regulated by mechanisms linked to the [Ca2+] i 
[11,14]. The period of neuronal development involves 
dynamic alterations in the structure and position of 
cells in the CNS during cell migration, neurite out- 
growth and synaptogenesis. Several findings indicate a 
narrow range of the [Ca2+]i for optimal neurite out- 
growth and growth-cone motility [14,15,30,37]. Mainte- 
nance of intracellular Ca 2+ homeostasis during devel- 
opment is, therefore, of major importance. This 
homeostasis i maintained by the concerted action of 
CaZ+-importing and -exporting systems [4,5,16,22]. Cy- 
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tosolic free Ca 2+ ions in both neuronal and glial cells 
can also bind in a fast but transient way to neuronal or 
glial intracellular CaZ+-binding proteins (CaBPs) [t,3], 
like calbindin-D28k, parvalbumin (PV) and S-100/3. 
Although little is known yet about the functions of 
CaBPs, these CaBPs belong to a group often defined 
as "buffer" proteins because of their presumed Ca 2+- 
buffering capacities [3,13,17]. 
The expression of a neuronal and a glial representa- 
tive of CaBPs, PV and S-100/3, respectively, is subject 
of this study. PV is expressed in a subpopulation of 
fast-firing cells some of which are GABA interneurons. 
By influencing the activity of CaZ+-dependent K + 
channels, it is thought o regulate the firing frequency 
of neurons [6]. In this respect, the ontogenic appear- 
ance of the protein has been reported to be in tempo- 
ral association with the beginning of physiological ac- 
tivity of certain inhibitory neurons [35]. PV is also 
suggested to protect neurons against excessive [Ca2+]i 
in pathological conditions, like ischemia or seizures 
[23,34]. The other CaBP that is subject of this study is 
the glial S-100fl. S-100 is involved in the regulation of 
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several enzymatic activities [20,27] and interacts with 
cytoskeletal functions [8,27,31,33]. Because glial cells 
are able to secrete S-100 [33], these effects are present 
not only in astroglial cells [32] but also in neurons. In 
this way, S-100 is thought o stimulate growth of sero- 
tonergic neurons [2,40]. The above-mentioned ffects 
of S-100 on growth and proliferation of cells in the 
nervous ystem led to the suggestion that the protein 
may help coordinate neuronal development. 
We recently reported that pre- and early-postnatal 
hypoxia transiently retarded the ingrowth of serotoner- 
gic and cholinergic fibers in neocortex and hippocam- 
pus [26]. The effects of such perinatal hypoxic events 
were also reflected in the impaired adult cognitive and 
motivational behaviors in which the above-mentioned 
neurotransmitter systems play a prominent role [24-26]. 
Cytosolic neuronal Ca 2+ overload in vulnerable brain 
regions, like cortex and hippocampus elicited by the 
perinatal hypoxia [7,38], may well be responsible for 
the observed anatomical and behavioral effects. This 
hypothesis finds support in the finding that chronic 
perinatal administration of the L-type Ca 2+ channel 
antagonist nimodipine during hypoxia prevented both 
suppression of cholinergic and serotonergic innervation 
of cortex and hippocampus [26] as well as behavioral 
abnormalities [24,25]. The neuroprotective action of 
the Ca 2+ antagonist during perinatal hypoxia may be 
caused by a decreased Ca 2+ influx. Another option 
may be the influence of nimodipine on the Ca 2+- 
buffering capacity of developing neuronal and glial 
cells. The studies on the effects of nimodipine during 
development so far have been restricted to its neuro- 
protective character in combination with hypoxic events 
while the action of nimodipine in normal brain devel- 
opment remains unclear. Therefore, we investigated 
the early-postnatal effect of chronic perinatai nimodi- 
pine treatment on the distribution of the neuronal 
CaBP PV and glial S-100/3 in neocortex and hippocam- 
pus. The effect of nimodipine on the expression of 
calbindin D-28k, being another neuronal CaBP, was 
presented in another manuscript (P.G.M. Luiten, sub- 
mitted). The study of these proteins may yield further 
insight in neuronal and glial mechanisms of intracellu- 
lar Ca 2+ balance during development. 
2. Materials and methods 
2.1. Animals 
The dams were housed in a temperature- and light-controlled 
room (21 _+ 1°C; 12/12 h l ight/dark cycle, lights on at 07:00). The day 
of birth was taken as postnatal day (PD) 1. Within the first 2 days 
after delivery, the litters were reduced to eight per nest. In total, 57 
male pups were sacrificed at PD 5, 7, 10, 14 and 20 from the two 
groups of animals. To an age group, only one single pup per nest was 
used to avoid the effect of litter. 
2.2. Treatment 
Pregnant rats were treated with nimodipine (1000 ppm BAY e 
9736 in daily food), starting at postconceptual day 11. Control 
animals received placebo food pellets. After delivery, the treatment 
was continued throughout he experiment. The selection of the 
single dose of the Ca 2+ antagonist was based on the results of 
previous immunocytochemical and behavioral studies performed in 
this laboratory [24-26]. 
2.3. Immunocytochemical procedure 
The rat pups were transcardially perfused under deep pentobar- 
bital anesthesia with cold heparinized saline. After blood removal, 
the prerinse was followed by a fixative containing 4% paraformalde- 
hyde and 0.2% picric acid in 0.1 M phosphate buffer (pH = 7.4). The 
brains were removed from the skull, postfixed for 6 h in the same 
fixative and cryoprotected overnight at 4°C in 30% buffered sucrose. 
Coronal sections of 20 ~zm were cut on a cryostat microtome and 
collected in phosphate-buffered saline (PBS) (0.01 M, pH = 7.4). The 
tissue sections were preincubated for 15 min in 0.01% H20 2 in PBS, 
subsequently rinsed in PBS and immersed for 30 min in 5% normal 
sheep (for PV-staining) or normal goat (in case of S-100-staining) 
serum to reduce aspecific binding in the following step. Next, the 
sections were incubated overnight at 4°C with the first antibody 
(respectively, monoclonal mouse anti-PV IgG (Sigma); 1:2000 in 
PBS and polyclonal rabbit anti-S-100/3 (Sigma); 1:10.000 in PBS). 
After rinsing, sections were incubated again in appropriate normal 
sera for 30 min and subsequently exposed to biotinylated sheep 
anti-mouse IgG (Zymed, 1 : 200 in PBS, 2 h at room temperature) or
goat anti-rabbit IgG (Zymed, 1:50 in PBS, 2 h at at room tempera- 
ture). This step was followed by incubation in streptavidin-HRP 
(Zymed, 1:200 in PBS, 2 h at room temperature) or rabbit PAP 
(Zymed, 1:500 in PBS, 2 h at room temperature). Finally, the 
tissue-bound peroxidase was visualized by reaction with diaminoben- 
zidine (30 rag/100 ml Tris-HCl) and 0.01% H20 2. Sections of 
placebo- and nimodipine-treated animals were pooled and simulta- 
neously processed for the PV and S-100/3 immunostainings. Stan- 
dard control experiments were performed by omission of the primary 
antibody, always yielding absence of detectable immunolabeling. 
2.4. Quantitative analys& 
Quantitative analysis was carried out by visual cell counts of 
selected hippocampal and cortical areas. Two coronal sections were 
selected at the level of the dorsal hippocampus corresponding to the 
anterior-posterior coordinate -3 .2  to -3 .8  mm relative to Bregma 
in the adult rat according to the brain atlas of Paxinos and Watson 
[28]. Hippocampal and cortical cell counts were performed bilaterally 
and the mean values of four counts per animal were processed for 
subsequent s atistical analysis. 
All visible immunoreactive PV neurons were counted within the 
layers of the parietal cortex defined by Zilles [41] as the Parl  area 
and in the retrosplenial granular cortex (RSG). No distinction was 
made between light and strong immunoreactivity. In the dorsal 
hippocampus, the cell number was added up over the three layers of 
CA1 and CA3, respectively. 
The development of S-100fl in glial cells was also studied at the 
brain level mentioned above. Since the density of S-100fl-positive 
glial cells was relatively high, cells were counted within a specified 
area of an ocular square grid (unit area: 7.9 p~m× 79 p.m at a ×200 
magnification). S-100-positive cells were quantified in Parl and in 
hippocampal layers of CA1 and CA3. 
The number of animals in the age groups of 5-, 7-, 10-, 14- and 
20-day-old rats varied from three to eight. 
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2.5. Statistic~ 3. Results 
The results are presented as mean _+ S.E.M. One-way ANOVA 
was applied for statistical evaluation of treatment effects within age 
groups. A P level of < 0.05 was taken as statistical significance for 
the tests. 
3.1. Normal  distribution o f  PV-posit ice interneurons 
At  PD 5, PV- immuno labe led  in terneurons  cou ld  not  
be  detected  in h ippocampus  or neocor tex .  F rom PD 7,
Fig. 1. Photomicrographs of PV (A-D) and S-100/~ (E,F) in hippocampus and eocortex of nimodipine- (left panel) and placebo-treated animals 
(right panel). A,B: low-power photomicrograph s owing PV-positive cells in hippocampus of nimodipine- (A) and placebo-treated (B) animal at 
PD 10, demonstrating higher number of PV-positive interneurons (arrows) in CA1-CA4 of nimodipine-treated rat. C,D: cell bodies (arrows) and 
processes (arrowheads) labeled in retrosplenial granular cortex (PD 10). Less cells and processes are stained in placebo-treated animals. E,F: 
S-100-positive astrocytes in layers I- I I I  in parietal cortex (PD 7). Radial glial fibers (arrowheads) are much more distinct in nimodipine-treated 
rats. Bars in A,B 100 ptm; in C,D 50 ~m and in E,F 50 p~m. 
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cells appeared in the dorsal hippocampal subicular 
area and CA3. In the neocortex, PV interneurons 
started to appear in the RSG and some sparse cells in 
the parietal cortex. In this early phase, the staining of 
the cells was still very light and processes were only 
faintly visible. At PD 10, the number and staining 
intensity of labeled cells increased in the hippocampal 
subiculum and CA3 and CA4. Interneurons also be- 
came visible in hippocampal CA1. In Parl and RSG, 
the majority of PV neurons were situated in pyramidal 
cell layer V. At PD 14, interneurons started to appear 
also in cortical layers II, III and VI and, at PD 20, 
positively labeled cells were seen in all layers. Staining 
intensity and length of cell processes increased gradu- 
ally with increasing age. 
3.2. Normal distribution of S-lO0[3-positiue glial cells 
S-100/3-positive glial cells were already present in 
large amounts in neocortical brain areas as well as in 
hippocampus at PD 5. Many of the S-100-positive cells 
in the neocortex could be classified as radial glial cells 
because of the high amount of extending immunoposi- 
tive radial fibers (Fig. 1E,F). In Par1, labeled cells 
appeared in the classical inside-out organization; many 
cells present in the deeper cortical layers IV-VI  but 
very little in the upper layers I- I I I .  In all hippocampal 
areas, many positively stained glial cells were observed 
with the highest density in subiculum and CA3 and less 
in CA1 and dentate gyrus. From PD 7 to 10, the 
density of labeled cells decreased slightly in hippocam- 
pal CA3 and increased in the other hippocampal reas. 
In Parl, the number of cells remained stable in layers 
IV-VI  and increased in upper layers I-I I I .  From PD 
10, the adult distribution pattern in the selected brain 
areas was reached since the number of S-100-positive 
cells did not show any further increase. 
3.3. Effect of perinatal nimodipine tr atment on deuelop- 
ment of PV- and S-lO0[3-positiue cells 
Number of PV-positiue cells 
Perinatal nimodipine treatment increased the num- 
ber and enhanced staining intensity of PV-positive 
interneurons in all neocortical and hippocampal re- 
gions studied at PD 10 (Fig. 2). The accumulated cell 
number in stratum oriens, pyramidale and radiatum of 
CA1 (Fl,12 = 6.0; P = 0.03) and CA3 (F1.12 = 6.2; P = 
0.03) was significantly higher in nimodipine-treated 
animals (Fig. 1A,B). In layer V of Parl and RSG (Fig. 
1C,D), the difference between placebo- and nimodip- 
ine-treated groups was even stronger (Fl.~2 = 9.5; P = 
0.009) and (FL~ 2 = 21.3; P= 0.001, respectively). At 
PD 14, PV-positive interneurons also started to appear 
in the more superficial layers of Par1 and RSG. How- 
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Fig. 2. Effects of nimodipine administration on number of PV-positive cells in hippocampal CA1 and CA3, in layer V of parietal cortex (PAR) 
and in RSG at PD 10 and 14. Mean + S.E.M. values are shown. * P < 0.05; ** P < 0.01, determined by one-way ANOVA. Number of animals 
used per group: PD 10: placebo (n = 8); nimodipine (n = 6). PD 14: placebo (n = 5); nimodipine(n = 6). 
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Fig. 3. Effects of nimodipine administration on number of S-100fl-positive astrocytes per unit area in layers I-V1 of parietal cortex at PD 5, 7, 10 
and 14. Mean 5: S.E.M. values are shown. ** P < 0.01; *** P < 0.001, determined by one-way ANOVA. Number of rats used per group: PD 5: 
plac (n = 8); nimo (n = 3). PD 7: plac (n = 4); nimo (n = 7). PD 10: plac (n = 6); nimo (n = 5). PD 14: plac (n = 6); nimo (n = 6). 
any treated and control cases was significant. At PD 20 
(data not shown), also no differences between the 
groups were present. 
Number of S-lO03-positive cells 
No differences could be revealed between placebo- 
and nimodipine-treated animals in number of im- 
munopositive glial cells in hippocampal regions. For 
that reason, no results of cell counts in hippocampus 
are shown. In Fig. 3, the number of S-100/3 cells per 
unit area (79 x 7.9 ~m) in the cortical regions is pre- 
sented at PD 5, 7, 10 and 14. At PD 5, significantly 
more S-100 cells were counted in layer I (FI, 9 = 28.5; 
P = 0.001) and layers II and III (El, 9 = 37.7; P = 0.000) 
of nimodipine-treated rats compared with placebo- 
treated animals (Fig. 1E,F). In the deeper layers IV-VI, 
no significant differences were present at PD 5. At PD 
7, the differences een at PD 5 still existed both in 
layer I (F1, 8 = 56.7; P = 0.000) and layers II and III 
(Ft. 8 - 41,0; P = 0.000). At PD 10 and 14, the nimodip- 
ine- and placebo-treated cases showed similar numbers 
of immunoreactive glia. Comparison of ages showed 
that adult patterns in the deeper cortical ayers IV-VI  
were reached already at PD 5 whereas the more super- 
ficial layers I - I I I  yielded an adult distribution at PD 
10. 
4. Discussion 
The present study shows the effects of chronic peri- 
natal administration of the Ca 2÷ antagonist nimodip- 
ine on the development of PV and S-100/3 immunore- 
activity in the rat neocortex and hippocampus. The 
data indicate that the development of PV and S-100 
immunoreactivity in defined postnatal brain regions is 
accelerated in nimodipine-treated animals. The ob- 
served developmental pattern of PV immunoreactivity 
in neurons and S-100~ in glial cells in placebo-treated 
animals is in agreement with previous repots  [9,35,36], 
The effect of nimodipine appears to be transient as 
it could be observed only in the initial phase of expres- 
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sion of both PV and S-100. The normal onset of 
S-100/3 immunoreactivity in glial cells precedes that of 
PV in neuronal cells. This probably causes nimodipine 
to affect the appearance of S-100 at PD 5 and 7 
whereas the effect on PV expression was present first 
and only at PD 10. It is not clear why nimodipine 
affects the onset of the CaBPs in specific regions. If it 
would be a general effect on the onset of expression of 
the described proteins, one would also expect acceler- 
ated development of PV in upper layers of the cortex. 
Since this is not the case, it appears that nimodipine 
exerts a cell-type and region-specific action, possibly 
based on a differential temporal expression of Ca 2~ 
channels during development. 
By antagonizing the Ca2+ influx through voltage-de- 
pendent L-type Ca 2+ channels [19], nimodipine is sug- 
gested to offer protection against a deranged Ca 2~ 
balance during anoxic or ischemic insults [38]. In view 
of the hypothesized Ca 2 +-buffering capacities of CaBPs, 
the accelerated expression of PV and S-100 by perina- 
tal nimodipine might offer another route of cellular 
protection against a damaging Ca 2+ influx. Perinatal 
nimodipine administration not only accelerates the on- 
togeny of PV and S-100 proteins but also of calbindin 
D-28k (P.G.M. Luiten et al., submitted). The protec- 
tive effect of CaBPs against a high [Ca2+]i, however, is 
still in question. In a number of studies, CaBPs are 
suggested to offer cellular protection against abnormal 
increases in [Ca2+] i during ischemia and anoxia 
[17,23,29,34,39]. In other studies, however, no consis- 
tent association between the expression of CaBPs and 
the predisposition of neurons to ischemic cell death 
was found [1,12]. 
Nimodipine application around birth not only accel- 
erates the onset of CaBPs. Chronic perinatal nimodi- 
pine administration combined with mild postnatal as- 
phyxia caused a transient increase in serotonergic and 
cholinergic fiber ingrowth in hippocampus and cortex 
between PD 5 and 10 [26]. These findings, together 
with the current results, suggest hat perinatal applica- 
tion of nimodipine accelerates everal parameters in 
various transmitter systems during the process of matu- 
ration. The nimodipine effects on growth processes in 
the brain can not be accounted for simply in terms of 
general acceleration or deceleration of development. 
Brain and body weights of control- and nimodipine- 
treated animals within the age groups used in the 
present study were similar. 
The effect of nimodipine can be elicited via a num- 
ber of mechanisms. Given the importance of the [Ca 2+ ]i 
in neuronal growth-cone behavior [14,15], it is tempting 
to propose an effect of nimodipine on growth accelera- 
tion by blockade of the L-type Ca 2+ current [19]. This 
suggestion is supported by the finding that also certain 
growth factors act by reducing Ca 2+ levels in the cell 
[18]. Nimodipine administration may optimalize growth 
conditions by holding the [Ca2+]i on the so-called 
"calcium set-point" [15] by CaBPs. 
The present results show an effect of perinatal ni- 
modipine administration on the developmental time of 
onset of neuronal and glial CaBPs. Retardation of 
ingrowth of cholinergic and serotonergic fibers after 
perinatal hypoxic events was also of a transient nature 
[26]. The behavioral performance, which we associated 
with the hypoxic insult, however, was permanently dis- 
turbed [24,25]. This indicates that, although placebo- 
treated animals apparently catch up with the delay in 
neuronal development of certain brain systems, the 
organization of the brain may remain structurally dif- 
ferent after perinatal nimodipine treatment. 
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